RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Transcranial Magnetic Stimulation for Schizophrenia

This is a single-site, sham-controlled, randomly assigned trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients.

Official registry: https://clinicaltrials.gov/study/NCT05389787 · Northwell Health · enrollment listed as 40

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Transcranial Magnetic Stimulation. The registry lists allocation as randomized. This is a single-site, sham-controlled, randomly assigned trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia.

They plan to enroll about 40 people at New York. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

Interventions: Transcranial Magnetic Stimulation

Primary outcome (registry wording): Cerebellar function

Who it is for (from inclusion criteria)

Ages 18 Years to 60 Years
Male or female subjects 18 to 60 years of age
DSM-V diagnosis of schizophrenia spectrum disorders

Who the registry excludes

Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders
Lifetime diagnosis of ataxia or other cerebellar disorders
Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders
Any active general medical condition or CNS disease which can affect cognition or response to treatment
Substance dependence or abuse in the past six months
TMS within three months or ECT within six months
Pregnancy as indicated by self-report

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

Zucker Hillside Hospital — New York, New York (recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 1 / Phase 2Houston, Texas

Phase 1 / Phase 2: testing Ocrelizumab infusion for Schizo-Affective Type of Psychosis

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and also feeling that other people do not like them.

NCT03971487 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute

RecruitingPhase 2Taichung

Phase 2: testing NMDAE plus AO for Schizophrenia

Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too.

NCT04959201 · Official ClinicalTrials.gov record · China Medical University Hospital

RecruitingNot a traditional drug phaseZurich, Canton of Zurich

Not a traditional drug phase: Motivational Interviewing for Psychosis

Psychotic disorders are associated with high levels of distress, limitations in quality of life, and a high risk of chronification for those affected. The treatment guidelines recommend combining the pharmacological treatment with psychotherapeutic methods, starting already in the acute phase.

NCT05911529 · Official ClinicalTrials.gov record · Psychiatric University Hospital, Zurich

FAQ about this NCT record

Is NCT05389787 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05389787?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05389787?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary